Faculty Summaries
Denise C Connolly, PhD
Denise C. Connolly, PhD
Associate Professor
Office Phone: 215-728-1004
Fax: 215-728-2741
Office: W310

2010 - present

  • Liu, H.*, Xiao, F.*, Serebriiskii, I.G., O’Brien, S.W., Maglaty, M.A., Astsaturov, I.,  Martin, L.P., Litwin, S., Proia, D.A., Golemis, E.A. and Connolly, D.C. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.Clin. Cancer Res. 2013 Jul 30. doi: 10.1158/1078-0432. CCR-13-1115 [Epub ahead of print].
    *Indicates co-first authorship.
  • Do, T.-V., Xiao, F., Bickel, L.E., Klein-Szanto, A.J., Pathak, H.B., Hua, X., Howe, C., O’Brien, S. W., Maglaty, M., Ecsedy, J.A., Golemis, E.A., Schilder, R.J., Godwin, A.K., and Connolly, D.C. Aurora kinase A mediates epithelial ovarian cancer migration and adhesion. Oncogene. 2013 Jan 21. doi: 10.1038/onc.2012.632. [Epub ahead of print].
  • Lara, H.,  Wang, Y., Beltran, A.S.,  Juárez-Moreno, K., Yuan, X., Kato, S., Leisewitz, A., Cuello Fredes, M., Licea, A.F., Connolly, D.C., Huang, L. and Blancafort, P. Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J. Biol. Chem. Epub ahead of print. PMID: 22782891
    Hensley, H.H., Roder, N.A., O’Brien, S.W., Bickel, L.E., Xiao, F., Litwin S., and Connolly, D.C. 2012. Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice. Neoplasia 14:451-462
  • Ratushny, V., Pathak, H.B., Beharry, N. Tikhmyanova, N., Xiao, F., Li, T., Litwin, S. Connolly, D.C., Yen, T.J. Weiner, L.M., Godwin, A.K. and Golemis, E.A. 2012. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene, 31:1217-1227.
  • Rozmiarek H, Connolly DC. Response to Protocol Review Scenario: Specify all medications. Lab Anim (NY). 2011 Mar;40(3):66-7
  • Quinn, B.A., Xiao, F, Bickel, L., Marin, L., Hua, X., Klein-Szanto, A. and Connolly, D.C. 2010. Development of a syngeneic mouse model of epithelial ovarian cancer. Journal of Ovarian Research 3:24.
  • Williams, R.M., Flesken-Nikitin, A., Ellenson, L.H., Connolly, D.C., Hamilton, T.C., Nikitin, A.Y., Zipfel, W.R. Strategies for high resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. Transl. Oncol. 3:181-194, 2010. PMID:20563260
  • Deng S, Yang XJ, Lassus H, Liang S, Kaur S, Ye QR, Li CS, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang YC, Montone K, Butzow R, Coukos G, Zhang L. Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers. Plos One. 2010 Apr;5(4):E10277.

2000 - 2009

  • Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One. 2009;4(12):e8404.
  • Connolly DC, Hensley HH. Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. Curr Protoc Pharmacol. 2009 Jun 1;45:14 12 1-14 12 26.
  • Connolly DC. Animal models of ovarian cancer. Cancer Treat Res. 2009;149:353-91.
  • Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M, Egleston BL, Klein-Szanto A, Pugacheva EN, Hardy RR, Wolfson M, Connolly DC, Golemis EA. NEDD9 Promotes Oncogenic Signaling in Mammary Tumor Development. Cancer Res. 2009 Sep;69(18):7198-206.
  • Hamilton TC, Connolly DC, Cairns P. Can mouse models aid in the early detection of human cancer. Cancer Biomarkers. 2008;4(3):127.
  • Liang S, Yang N, Pan Y, Deng S, Lin X, Katsaros KF, Hamilton TC, Connolly DC, Coukos G, Zhang L. Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PLoS ONE. 2009 Jan 27;4(1):e4295. Epub.
  • Choi YS, Hoory T, Monie A, Wu A, Connolly D, Hung C-F. α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine. 2008;26(46):5855-5863.
  • Melikechi N, Ding H, Rock S, Marcano OA, Connolly D. Laser-induced breakdown spectroscopy of whole blood and other liquid organic compounds. In: Optical Diagnostic and Sensing VIII (Cote, G., Priezzhev, A.V., eds.). Proceeding of SPIE 6863, 68630O1-7. 2008;DOI:10.1117/12.761901.
  • Melikechi N, Ding H, Marcano OA, Rock S, Connolly D. Laser-induced breakdown spectroscopy of alcohols and proteins solutions. AIP Proceedings: Atomic, Molecular, and Optical Physics. 2008;992:1177-1182.
  • Hensley H, Quinn BA, Wolf RL, Litwin S, Mabuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol. Ther. 2007;6:1717-1725, 2007.
  • Mabuchi S, Altomare DA, Connolly DC, Klein Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR. RAD001 delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007;67:2408-2413.
  • Pieretti-Vanmarcke R, Donahoe PK, Pearsall L, Connolly DC, Dinulescu DM, Halpern EF, Seiden MV, McLaughlin DT. MIS enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc. Natl. Acad Sci U.S.A. 2006;103:17426-17431.
  • Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, MacLaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem-cell characteristics and Müllerian inhibiting substance responsiveness. Proc Natl Acad Sci USA. 2006;103:11154-11159.
  • Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, Berek J. Progress in ovarian cancer research: Proceedings of the 5th Biennial Ovarian Cancer Research Symposium. Int J Gynecol Cancer. 2006;16:463-469.
  • Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT. Recombinant human Müllerian inhibiting substance inhibits long term growth of MIS type II recptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res. 2006;12:1593-1598.
  • Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res. 2006;66:2527-2531.
  • Cvetkovic D, Connolly DC, Hamilton TC. Molecular biology and molecular genetics of ovarian, primary peritoneal, and fallopian tube cancer. In: Gynecologic Cancer: Controversies in Management (Gershenson, McGuire, Gore, Quinn, Thomas, eds.), Section 3, Chapter 28, pp. 385-398. Elsevier Science, Philadelphia, PA, 2004.
  • Danielson AJ, Christensen TA, Lovejoy CA, Adelsman MA, Connolly DC, Maihle NJ. Membrane localization of v-ERBB is required but not sufficient for ligand-independent transformation. Exp Cell Res. 2004 296:285-293.
  • Nikitin AY, Connolly DC, Hamilton TC. Pathology of ovarian neoplasms in genetically modified mice. Comp Med. 2004;54:26-28.
  • Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5:19-24.
  • Hamilton TC, Connolly DC, Daly MB, Ozols RF. Ovarian Cancer Prevention. 39th ASCO Annual Meeting (Educational Book), pp. 283-290, 2003.
  • Hamilton TC, Connolly DC, Nikitin AY, Garson K, Vanderhyden BC. Translational research in ovarian cancer: a must. Int J Gynecol Cancer. 2003;13(Suppl 2):220-230.
  • Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole T, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female mice chimeric for the expression of the SV40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 2003;63:1389-1397.
  • Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst. 2002;94:522-528.
  • Selvakumaran M, Bao R, Crijns APG, Connolly DC, Weinstein JK, Hamilton TC. Ovarian epithelial cell-lineage specific gene expression using the promoter of a retroviral-like element. Cancer Res. 2001;61:1291-1295.
  • Wu R, Connolly DC, Ngelangel C, Bosch FX, Muñoz N, Cho KR. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene. 2000;19:5543-5546.
  • Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, Jones RW, Bosch FX, Muñoz N, Cho KR. Loss of Fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res. 2000;6:3505-3510.
  • Wu R, Connolly DC, Cho KR. Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J Natl Cancer Inst. 2000;92:338-344.
  • Connolly DC, Katabuchi H, Scully RE, Cliby WA, Lei RY, Cho KR. Somatic mutations in the STK11/LKB1 gene are uncommon in rare gynecological tumor types associated with Peutz-Jeghers syndrome. Am J Pathol. 2000;156:339-345.

1990 - 1999

  • Wu R, Connolly DC, Ren X, Fearon ER, Cho KR. Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q22-24 are infrequent in ovarian carcinoma. Neoplasia 1999;1:311-314.
  • Szych, C., Staebler, A., Connolly, D.C., Wu, R., Cho, K. R., Ronnett, B.M. Molecular genetic evidence supporting the appendiceal origin of pseudomyxoma peritoneii in women. Am J Pathol. 1999 154:1849-1855.
  • Brat DJ, James DE, Jedlicka AE, Connolly DC, Chang E, Castellani RJ, Schmid M, Schiller M, Carson DA, Burger PC. Molecular genetic alterations in radiation-induced astrocytomas. Am J Pathol. 1999;154:1431-1438.
  • Geng L, Connolly DC, Isacson C, Ronnett BM, Cho KR. Atypical immature metaplasia (AIM) of the cervix: is it related to high-grade squamous intraepithelial lesion (SIL)? Hum Pathol. 1999;30:345-351.
  • Baron AT, Lafky JM, Connolly DC, Peoples J, O’Kane DJ, Suman VJ, Boardman CH, Podratz KC, Maihle NJ. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. J Immunol Methods. 1998;219:23-43.
  • Greenspan DL, Connolly DC, Wu R, Lei RL, Vogelstein JTC, Kim Y-K, Mok JE, Munoz N, Bosch FX, Shah K, Cho KR. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 1997;57:4692-4698.
  • Kessis TD, Connolly DC, Hedrick L, Cho KR. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 1996;13:427-431.
  • Gill JS, Connolly DC, McManus MJ, Maihle NJ, Windebank AJ. Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglia. J Neurochem. 1996;66:963-972.
  • McManus, M.J., Connolly, D.C., Maihle, N.J. Tyrosine phosphorylated substrates in cells transformed by tissue-specific c-erbB1 mutants. J Virol. 1995 69:3631-3638.
  • Eldredge ER, Korf GM, Christensen TA, Connolly DC, Getz MJ, Maihle NJ. Activation of c fos gene expression by a kinase-deficient epidermal growth factor receptor. Mol Cell Biol. 1994;14:7527-7534.
  • Connolly DC, Toutenhoofd SL, Maihle NJ. Tyrosine kinase activity may be necessary, but is not sufficient for c-erbB mediated tumorigenicity. J Virol. 1994;68:6804-6810.
  • Bell S, Connolly DC, Maihle NJ, Degen J. Differential modulation of plasminogen activator gene expression by oncogene-encoded tyrosine kinases. Mol Cell Biol. 1993;13:5888-5897.